AYTU
Aytu BioPharma, Inc.NASDAQHealthcare$2.68-0.75%ClosedMarket Cap: $21.7M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.88
P/S
0.34
EV/EBITDA
-0.85
DCF Value
$-21.79
FCF Yield
-3.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
66.0%
Operating Margin
-13.9%
Net Margin
-39.0%
ROE
-107.2%
ROA
-20.0%
ROIC
-12.8%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $15.2M | 60.0% | $-2.0M | $-10.6M | $-1.05 | — |
| Q1 2026 | $13.9M | 66.1% | $-1.5M | $2.0M | $-0.08 | — |
| Q4 2025 | $15.1M | 67.8% | $-7.6M | $-19.8M | $-2.92 | — |
| FY 2025 | $66.4M | 69.0% | $-7.8M | $-13.6M | $-2.16 | — |
| Q3 2025 | $18.5M | 69.4% | $2.4M | $4.0M | $0.21 | — |
| Q2 2025 | $16.2M | 66.5% | $-1.7M | $788.0K | $-0.26 | — |
| Q1 2025 | $16.6M | 72.3% | $-930.0K | $1.5M | $0.16 | — |
| Q4 2024 | $18.0M | 66.2% | $-3.6M | $-4.6M | $-0.83 | — |
| FY 2024 | $65.2M | 75.3% | $-1.6M | $-15.8M | $-2.86 | — |
| Q3 2024 | $14.0M | 73.9% | $-1.6M | $-2.9M | $-0.52 | — |
| Q2 2024 | $18.7M | 77.9% | $3.1M | $-220.0K | $-0.04 | — |
| Q1 2024 | $17.8M | 73.2% | $-867.0K | $-8.1M | $-1.48 | — |